Patents by Inventor Sha-Mei Liao

Sha-Mei Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding anti-Factor P antibodies
    Patent number: 10865237
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 15, 2020
    Assignee: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P
    Publication number: 20180327486
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Application
    Filed: May 7, 2018
    Publication date: November 15, 2018
    Applicant: Novartis AG
    Inventors: Leslie Ngozi Anuna JOHNSON, Ute JAEGER, Yong-In KIM, Christian Carsten Silvester KUNZ, Igor SPLAWSKI, Michael ROGUSKA, Joy GHOSH, Barbara BRANNETTI, Michael STEFANIDAKIS, Sha-Mei LIAO
  • Compositions comprising antibodies targeting factor P
    Patent number: 9988440
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P
    Publication number: 20150158936
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Application
    Filed: June 19, 2014
    Publication date: June 11, 2015
    Applicant: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester KUNZ, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • Antibodies that bind factor P
    Patent number: 9051365
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Sha-Mei Liao, Michael Stefanidakis
  • MEKK1 molecules and uses thereof
    Publication number: 20050084884
    Abstract: The invention provides full-length, human isolated nucleic acids molecules, designated MEKK1 nucleic acid molecules, which encode a MEKK family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MEKK1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MEKK1 gene has been introduced or disrupted. The invention still further provides isolated MEKK1 proteins, fusion proteins, antigenic peptides and anti-MEKK1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: August 31, 2004
    Publication date: April 21, 2005
    Inventors: Vito Palombella, Sha-Mei Liao
  • MEKK1 molecules and uses thereof
    Patent number: 6818427
    Abstract: The invention provides full-length, human isolated nucleic acids molecules, designated MEKK1 nucleic acid molecules, which encode a MEKK family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MEKK1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MEKK1 gene has been introduced or disrupted. The invention still further provides isolated MEKK1 proteins, fusion proteins, antigenic peptides and anti-MEKK1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: November 16, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Vito J. Palombella, Sha-Mei Liao